| Note | |
| | |
| Entity | Alveolar Rhabdomyosarcoma (ARMS) |
| Disease | ARMS is one subtype of a family of pediatric soft tissue tumors that is related to the skeletal muscle lineage. In contrast to the embryonal rhabdomyosarcoma (ERMS), the other major subtype in this family, ARMS often occurs in adolescents and young adults, with primary tumors located in the vicinity of skeletal muscle, such as in the extremities and trunk. |
| Prognosis | In contrast to the favorable outcome in most cases of ERMS, ARMS is associated with an unfavorable prognosis. In the IRS-IV clinical trial, the three year failure-free survival rate was 66% for patients presenting without metastatic disease and 16% for patients presenting with metastatic disease (compared to 83% and 37% for non-metastatic and metastatic ERMS, respectively). This unfavorable prognosis in ARMS is related to the propensity for early and wide dissemination, often involving bone marrow, and to poor response to chemotherapy. |
| Cytogenetics | Chromosomal studies identified nonrandom chromosomal translocations that distinguish the majority of ARMS tumors from ERMS and other pediatric solid tumors. The t(2;13)(q35;q14) translocation is the most prevalent and the t(1;13)(p36;q14) is identified in a smaller subset of cases. |
| Hybrid/Mutated Gene | The 2;13 or 1;13 chromosome translocation juxtapose the PAX3 gene on chromosome 2 or the PAX7 gene on chromosome 1 with the FKHR (FOXO1A) gene on chromosome 13 to generate two chimeric genes. These chimeric genes are transcribed to generate chimeric transcripts, of which the PAX3-FKHR and PAX7-FKHR transcripts are the most highly and consistently expressed of the pair of potential products. Based on RT-PCR assays for these chimeric transcripts, approximately 60% of ARMS cases express PAX3-FKHR and thus contain the t(2;13), 20% express PAX7-FKHR and thus contain the t(1;13), and 20% are fusion-negative. |
| |  |
| |
| a) Diagram of t(2;13)(q35;q14) and t(1;13)(p36;q14) chromosomal translocations generating PAX3-FKHR and PAX7-FKHR fusions b) Generation of chimeric genes by the t(2;13)(q35;q14) translocation in ARMS. The exons of the wild-type and fusion genes are shown as boxes above each map and the translocation breakpoint distributions are shown as line segments below the map of the wild-type genes. c) Comparison of wild-type and fusion products associated with the 2;13 and 1;13 translocations. The paired box, octapeptide, homeobox and fork head domain are indicated as open boxes, and transcriptional domains (DNA binding domain, DBD; transcriptional activiation domain, TAD; transcriptional inhibitory domain, TID) are shown as solid bars. The sites phosphorylated by Akt are indicated by stars, and the alternative splice in the paired box is shown by an arrowhead. The vertical dash line indicates the translocation fusion point. {Reproduced from: Barr (2001) Oncogene 20: 5736- 5746} |
| |
| Oncogenesis | The PAX3-FKHR and PAX7-FKHR chimeric genes encode fusion proteins that contain the intact DNA binding domain of PAX3 or PAX7 in the N-terminal region fused in frame with a C-terminal FKHR (FOXO1A) segment containing the transactivation domain. The chromosomal changes in ARMS result in high level expression, potent transcriptional activity, and constitutive nuclear localization of the PAX3-FKHR or PAX7-FKHR fusion products. The end result is exaggerated activity at multiple biological levels that converges to inappropriate activation of PAX3/PAX7 target genes and ultimately contributes to tumourigenic behavior. |
| | |
| | |
| Entity | Waardenburg syndrome (type I et III) |
| Disease | Waardenburg syndrome (WS) is an inherited autosomal-dominant disorder characterized by sensorineural hearing loss (of varying severity), dystopia canthorum (lateral displacement of inner corners of eye), and pigmentary disturbances of the eye, skin and hair. It is a common cause of inherited deafness in infants. Depending on additional symptoms, WS is classified into four types, WS1, WS2, WS3, and WS4, with only WS1 and WS3 being associated with PAX3 mutations. Deletions, insertion, base pair substitution, or dominant point mutations of PAX3 cause WS1 and WS3. WS3 (Klein-Waardenburg syndrome) is similar to WS1 but WS3 is also characterized by musculoskeletal abnormalities, usually involving the upper limbs. It should be noted that WS3 is often associated with deletions of the long arm of chromosome 2 involving multiples genes including PAX3 whereas WS1 is generally is associated with mutations within the PAX3 gene. WS2 is heterogenous, being caused by mutations in the MITF gene in some but not all affected families. WS4 is caused by mutations in the EDN3, EDNRB, or SOX10 ID genes. |
| | |
| | |
| Entity | Craniofacial-deafness-hand syndrome (CDHS) |
| Disease | Craniofacial-deafness-hand syndrome is inherited as an autosomal dominant mutation. CDHS shows clinical characteristics of the absence or hypoplasia of the nasal bones, profound sensorineural deafness, a small and short nose with slitlike nares, hypertelorism, short palpebral fissures, and limited movement at the wrist and ulnar deviations of the fingers. A missense mutation (Asn47Lys) in the paired domain (exon 2) of PAX3 was detected in a family of three (a mother and two children) first reported with this syndrome. |
| | |
| Missense mutation in the paired domain of PAX3 causes craniofacial-deafness-hand syndrome. |
| Asher JH Jr, Sommer A, Morell R, Friedman TB |
| Human mutation. 1996 ; 7 (1) : 30-35. |
| PMID 8664898 |
| |
| An exonic mutation in the HuP2 paired domain gene causes Waardenburg's syndrome. |
| Baldwin CT, Hoth CF, Amos JA, da-Silva EO, Milunsky A |
| Nature. 1992 ; 355 (6361) : 637-638. |
| PMID 1347149 |
| |
| PAX3 gene structure, alternative splicing and evolution. |
| Barber TD, Barber MC, Cloutier TE, Friedman TB |
| Gene. 1999 ; 237 (2) : 311-319. |
| PMID 10521655 |
| |
| Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. |
| Barr FG |
| Oncogene. 2001 ; 20 (40) : 5736-5746. |
| PMID 11607823 |
| |
| Predominant expression of alternative PAX3 and PAX7 forms in myogenic and neural tumor cell lines. |
| Barr FG, Fitzgerald JC, Ginsberg JP, Vanella ML, Davis RJ, Bennicelli JL |
| Cancer research. 1999 ; 59 (21) : 5443-5448. |
| PMID 10554014 |
| |
| Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. |
| Barr FG, Galili N, Holick J, Biegel JA, Rovera G, Emanuel BS |
| Nature genetics. 1993 ; 3 (2) : 113-117. |
| PMID 8098985 |
| |
| Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. |
| Barr FG, Qualman SJ, Macris MH, Melnyk N, Lawlor ER, Strzelecki DM, Triche TJ, Bridge JA, Sorensen PH |
| Cancer research. 2002 ; 62 (16) : 4704-4710. |
| PMID 12183429 |
| |
| PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. |
| Bennicelli JL, Advani S, Schäfer BW, Barr FG |
| Oncogene. 1999 ; 18 (30) : 4348-4356. |
| PMID 10439042 |
| |
| Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. |
| Bernasconi M, Remppis A, Fredericks WJ, Rauscher FJ 3rd, Schäfer BW |
| Proceedings of the National Academy of Sciences of the United States of America. 1996 ; 93 (23) : 13164-13169. |
| PMID 8917562 |
| |
| Pax-3 is required for the development of limb muscles: a possible role for the migration of dermomyotomal muscle progenitor cells. |
| Bober E, Franz T, Arnold HH, Gruss P, Tremblay P |
| Development (Cambridge, England). 1994 ; 120 (3) : 603-612. |
| PMID 8162858 |
| |
| Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. |
| Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM, Qualman SJ, Wharam MD, Donaldson SS, Maurer HM, Meyer WH, Baker KS, Paidas CN, Crist WM |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 ; 21 (1) : 78-84. |
| PMID 12506174 |
| |
| Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. |
| Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 ; 19 (12) : 3091-3102. |
| PMID 11408506 |
| |
| Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. |
| Davis RJ, Barr FG |
| Proceedings of the National Academy of Sciences of the United States of America. 1997 ; 94 (15) : 8047-8051. |
| PMID 9223312 |
| |
| Co-expression of alternatively spliced forms of PAX3, PAX7, PAX3-FKHR and PAX7-FKHR with distinct DNA binding and transactivation properties in rhabdomyosarcoma. |
| Du S, Lawrence EJ, Strzelecki D, Rajput P, Xia SJ, Gottesman DM, Barr FG |
| International journal of cancer. Journal international du cancer. 2005 ; 115 (1) : 85-92. |
| PMID 15688409 |
| |
| Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. |
| Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ 3rd, Emanuel BS, Rovera G, Barr FG |
| Nature genetics. 1993 ; 5 (3) : 230-235. |
| PMID 8275086 |
| |
| Pax-3, a novel murine DNA binding protein expressed during early neurogenesis. |
| Goulding MD, Chalepakis G, Deutsch U, Erselius JR, Gruss P |
| The EMBO journal. 1991 ; 10 (5) : 1135-1147. |
| PMID 2022185 |
| |
| Pax3: a paired domain gene as a regulator in PNS myelination. |
| Kioussi C, Gross MK, Gruss P |
| Neuron. 1995 ; 15 (3) : 553-562. |
| PMID 7546735 |
| |
| The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain. |
| Lam PY, Sublett JE, Hollenbach AD, Roussel MF |
| Molecular and cellular biology. 1999 ; 19 (1) : 594-601. |
| PMID 9858583 |
| |
| Pax3 functions at a nodal point in melanocyte stem cell differentiation. |
| Lang D, Lu MM, Huang L, Engleka KA, Zhang M, Chu EY, Lipner S, Skoultchi A, Millar SE, Epstein JA |
| Nature. 2005 ; 433 (7028) : 884-887. |
| PMID 15729346 |
| |
| Expression of PAX 3 alternatively spliced transcripts and identification of two new isoforms in human tumors of neural crest origin. |
| Parker CJ, Shawcross SG, Li H, Wang QY, Herrington CS, Kumar S, MacKie RM, Prime W, Rennie IG, Sisley K, Kumar P |
| International journal of cancer. Journal international du cancer. 2004 ; 108 (2) : 314-320. |
| PMID 14639621 |
| |
| Waardenburg syndrome. |
| Read AP, Newton VE |
| Journal of medical genetics. 1997 ; 34 (8) : 656-665. |
| PMID 9279758 |
| |
| Pax3 and Pax7 have distinct and overlapping functions in adult muscle progenitor cells. |
| Relaix F, Montarras D, Zaffran S, Gayraud-Morel B, Rocancourt D, Tajbakhsh S, Mansouri A, Cumano A, Buckingham M |
| The Journal of cell biology. 2006 ; 172 (1) : 91-102. |
| PMID 16380438 |
| |
| A Pax3/Pax7-dependent population of skeletal muscle progenitor cells. |
| Relaix F, Rocancourt D, Mansouri A, Buckingham M |
| Nature. 2005 ; 435 (7044) : 948-953. |
| PMID 15843801 |
| |
| A PANorama of PAX genes in cancer and development. |
| Robson EJ, He SJ, Eccles MR |
| Nature reviews. Cancer. 2006 ; 6 (1) : 52-62. |
| PMID 16397527 |
| |
| Craniofacial-deafness-hand syndrome revisited. |
| Sommer A, Bartholomew DW |
| American journal of medical genetics. Part A. 2003 ; 123 (1) : 91-94. |
| PMID 14556253 |
| |
| Previously undescribed syndrome of craniofacial, hand anomalies, and sensorineural deafness. |
| Sommer A, Young-Wee T, Frye T |
| American journal of medical genetics. 1983 ; 15 (1) : 71-77. |
| PMID 6859126 |
| |
| PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. |
| Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 ; 20 (11) : 2672-2679. |
| PMID 12039929 |
| |
| The mutational spectrum in Waardenburg syndrome. |
| Tassabehji M, Newton VE, Liu XZ, Brady A, Donnai D, Krajewska-Walasek M, Murday V, Norman A, Obersztyn E, Reardon W |
| Human molecular genetics. 1995 ; 4 (11) : 2131-2137. |
| PMID 8589691 |
| |
| An alternative splicing event in the Pax-3 paired domain identifies the linker region as a key determinant of paired domain DNA-binding activity. |
| Vogan KJ, Underhill DA, Gros P |
| Molecular and cellular biology. 1996 ; 16 (12) : 6677-6686. |
| PMID 8943322 |
| |
| Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. |
| Wachtel M, Dettling M, Koscielniak E, Stegmaier S, Treuner J, Simon-Klingenstein K, Bühlmann P, Niggli FK, Schäfer BW |
| Cancer research. 2004 ; 64 (16) : 5539-5545. |
| PMID 15313887 |
| |
